55200Rethinking personalized cancer therapy: targeting minimal residual disease in high-risk lymphoma patients [En savoir plus]HiRisk-HiGain - ANR-20-PERM-0009
ERA PerMed - 2020

Voir les documents associés 

Exporter

• Export XML
• Export RDF